Abstract 4340646: Efficacy of Beta-Blocker Therapy in Takotsubo Cardiomyopathy: A Systematic Review and Meta-Analysis

Background: Takotsubo cardiomyopathy (TTC) is a stress-induced condition with limited evidence-based treatment options. Beta-blockers are commonly used, yet their efficacy remains uncertain. This meta-analysis evaluates the impact of beta-blocker therapy on mortality and recurrence in TTC patients. Methods: We systematically searched PubMed, EMBASE, Cochrane Library, Web of Science, Google Scholar, and Semantic Scholar, alongside trial registries and grey literature, for studies from inception to March 2025. Included studies examined adult TTC patients treated with beta-blockers versus controls, reporting all-cause mortality and recurrence. Odds ratios (ORs) with 95% confidence intervals (CIs) were pooled using a random-effects model. Heterogeneity was assessed with I statistics, and publication bias was evaluated via funnel plots. A meta-regression explored ejection fraction (EF) as a moderator of mortality outcomes. Results: Nineteen studies (n=11,167 patients, predominantly female, mean age 59–74 years) were included. Beta-blocker therapy significantly reduced all-cause mortality by 28% (OR 0.72, 95% CI: 0.62–0.84, p=0.00; I=0.30) across 19 studies. Subgroup analyses showed a non-significant 21% reduction in 1-year mortality (OR 0.79, 95% CI: 0.54–1.16, p=0.23; I=0.52) and a significant 29% reduction in 2–5-year mortality (OR 0.71, 95% CI: 0.61–0.82, p=0.00; I=0.07). Recurrence decreased by 29% (OR 0.71, 95% CI: 0.52–0.97, p=0.03; I=0.57), with a mean follow-up of 2.6 years. Meta-regression showed no significant moderation of mortality by EF (p=0.638), suggesting consistent benefits across cardiac function levels. Conclusions: Beta-blockers significantly reduce long-term mortality and recurrence in TTC, with less clear short-term benefits and no variation by EF. These findings support their use in sustained TTC management, though randomized trials are needed to confirm causality and optimize protocols.

Authors

Institutions

Publication Details

Journal
Circulation
Published
2025-11-03
DOI
https://doi.org/10.1161/circ.152.suppl_3.4340646
Primary Topic
Takotsubo Cardiomyopathy and Associated Phenomena
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 4340646: Efficacy of Beta-Blocker Therapy in Takotsubo Cardiomyopathy: A Systematic Review and Meta-Analysis

Ashish Kumar Gupta, Merina Dongol, Ricardo Antonio Rodriguez Mejia, Arminder Singh et al.
Circulation
Takotsubo Cardiomyopathy and Associated Phenomena
article

Abstract 4340646: Efficacy of Beta-Blocker Therapy in Takotsubo Cardiomyopathy: A Systematic Review and Meta-Analysis

Ashish Kumar Gupta, Merina Dongol, Ricardo Antonio Rodriguez Mejia, Arminder Singh, Amol Bahekar
article en

Abstract

Background: Takotsubo cardiomyopathy (TTC) is a stress-induced condition with limited evidence-based treatment options. Beta-blockers are commonly used, yet their efficacy remains uncertain. This meta-analysis evaluates the impact of beta-blocker therapy on mortality and recurrence in TTC patients. Methods: We systematically searched PubMed, EMBASE, Cochrane Library, Web of Science, Google Scholar, and Semantic Scholar, alongside trial registries and grey literature, for studies from inception to March 2025. Included studies examined adult TTC patients treated with beta-blockers versus controls, reporting all-cause mortality and recurrence. Odds ratios (ORs) with 95% confidence intervals (CIs) were pooled using a random-effects model. Heterogeneity was assessed with I statistics, and publication bias was evaluated via funnel plots. A meta-regression explored ejection fraction (EF) as a moderator of mortality outcomes. Results: Nineteen studies (n=11,167 patients, predominantly female, mean age 59–74 years) were included. Beta-blocker therapy significantly reduced all-cause mortality by 28% (OR 0.72, 95% CI: 0.62–0.84, p=0.00; I=0.30) across 19 studies. Subgroup analyses showed a non-significant 21% reduction in 1-year mortality (OR 0.79, 95% CI: 0.54–1.16, p=0.23; I=0.52) and a significant 29% reduction in 2–5-year mortality (OR 0.71, 95% CI: 0.61–0.82, p=0.00; I=0.07). Recurrence decreased by 29% (OR 0.71, 95% CI: 0.52–0.97, p=0.03; I=0.57), with a mean follow-up of 2.6 years. Meta-regression showed no significant moderation of mortality by EF (p=0.638), suggesting consistent benefits across cardiac function levels. Conclusions: Beta-blockers significantly reduce long-term mortality and recurrence in TTC, with less clear short-term benefits and no variation by EF. These findings support their use in sustained TTC management, though randomized trials are needed to confirm causality and optimize protocols.

CirculationVol. 152(Suppl_3)
Fayetteville VA Medical Center (US), Cape Fear Valley Medical Center (US)
Openalex Percentile: Top 51%
Takotsubo Cardiomyopathy and Associated Phenomena
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.